MEG3 and non-small cell lung carcinoma: MEG3 can also enhance NSCLC sensitivity to cisplatin by sponging miR-21-5p and thereby upregulating SRY-box transcription factor 7 (SOX7) expression [135]; by sponging miR-141, MEG3 could overcome CRC cells chemoresistance to oxaliplatin and promote programmed cell death factor 4 (PDCD4) expression [129].